Clinical Trials Study
Copyright ©The Author(s) 2020.
World J Gastroenterol. Aug 14, 2020; 26(30): 4501-4522
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4501
Table 2 Inclusion and exclusion criteria of patients
Inclusion criteriaExclusion criteria
Conform with the diagnostic criteria of HBeAg (+) chronic hepatitis BInactive HBsAg (+) carriers
Conform with the pathogenesis and syndromes of kidney deficiencySerum a-fetoprotein abnormal
Age 30-65 yrPregnancy or breast feeding
ALT ≤ 40 IU/LCoinfection with HIV, HCV, HDV
HBsAg > 10 IU/mL and < 105 IU/mL HBV DNA (105-109 IU/mL)Histologic evidence of cirrhosis; Evidence of any other chronic liver disease
Liver biopsy: Liver histology showed Knodell HAI > 4, Ishak fibrosis score > 3 were also includedMental illness or any other serious systemic illness
VoluntaryInterferon-γ within 6 mo; Antivirus treatment with nucleoside
Abuse alcohol or illegal drugs; Allergic to the drug ingredients

  • Citation: Xing YF, Wei CS, Zhou TR, Huang DP, Zhong WC, Chen B, Jin H, Hu XY, Yang ZY, He Q, Jiang KP, Jiang JM, Hu ZB, Deng X, Yang F, Li FY, Zhao G, Wang LC, Mi YQ, Gong ZJ, Guo P, Wu JH, Shi WQ, Yang HZ, Zhou DQ, Tong GD. Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients. World J Gastroenterol 2020; 26(30): 4501-4522
  • URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4501.htm
  • DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4501